Perceptive Ups Trinity Biotech Stake via Deal Terms

On April 30, 2026, Perceptive Advisors LLC and its affiliates entered into a Limited Waiver and Third Amendment to their existing Credit Agreement with Trinity Biotech plc (TRIB). This amendment provided a limited waiver for certain financial covenant non-compliance and authorized an additional $2.5 million term loan. Significantly, the aggregate amount of indebtedness convertible into American Depositary Shares (ADSs) was increased from $60 million to $72.5 million. Furthermore, the minimum conversion price (Floor Price) was reduced from $1.03 per ADS to $0.5061 per ADS. Due to these adjustments, the reporting persons now beneficially own an aggregate of 3,424,019,957 ordinary shares, representing 9.9% of the class. This total includes shares issuable via warrants, the amended Convertible Note, and Milestone/Contingent Payment Obligations. The ownership is subject to a 9.9% Beneficial Ownership Cap, which prevents the exercise or conversion of these instruments if it would result in exceeding that threshold. The reporting persons include Perceptive Advisors LLC, Perceptive Credit Advisors LLC, Joseph Edelman, and two credit funds.